bmi glp 1 Patient flow. BMI, body mass index; GLP‐1RA, glucagon‐like peptide‐1 Eligibility criteria distribution by GLP-1

Doses of insulin or sulfonylureas may need adjustment when starting GLP-1 therapy to reduce hypoglycaemia risk

Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months

Pregnant patients exposed to Zepbound and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979)

11 Related Stories Blood ketone threshold may help predict weight loss success Muscle health plays crucial role in diabetes risk, study finds Popular diabetes drugs do not alter the risk of developing a blinding eye condition The cardiovascular benefits of semaglutide are attributed to several mechanisms beyond weight loss

suggests circumcision is linked to autism

By combining this innovative medical treatment with a holistic lifestyle approach, you can achieve sustainable weight loss and enhance your overall health